Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.
Kim A. Reiss Binder, MD
Advertisement
Articles by Kim A. Reiss Binder, MD
Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Dr. Binder on Data Regarding Rucaparib Maintenance in Pancreatic CancerPublished: April 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
3
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5